(NASDAQ: AQST) Aquestive Therapeutics's forecast annual revenue growth rate of 24.23% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.34%.
Aquestive Therapeutics's revenue in 2026 is $54,087,000.On average, 11 Wall Street analysts forecast AQST's revenue for 2026 to be $6,391,931,698, with the lowest AQST revenue forecast at $6,048,657,340, and the highest AQST revenue forecast at $6,866,114,704. On average, 11 Wall Street analysts forecast AQST's revenue for 2027 to be $8,675,867,156, with the lowest AQST revenue forecast at $6,420,673,865, and the highest AQST revenue forecast at $14,760,169,805.
In 2028, AQST is forecast to generate $13,661,942,885 in revenue, with the lowest revenue forecast at $11,931,137,259 and the highest revenue forecast at $16,381,780,297.